Liquid Biopsy

Research in liquid biopsy focuses on developing and applying non-invasive methods to detect and analyze biomarkers shed by tumors into bodily fluids, primarily blood. This field investigates the isolation and characterization of circulating tumor cells (CTCs), cell-free DNA (cfDNA), and other tumor-derived molecules. Techniques such as advanced biosensing, flow cytometry, and laser-based analysis are employed to identify genetic mutations, epigenetic alterations, and protein expression patterns associated with various cancers. The ultimate goal is to improve early cancer detection, monitor treatment response, and track disease recurrence with minimal patient discomfort.

This work holds significant relevance for Arkansas, a state with a notable burden of certain cancers. Advancements in liquid biopsy can contribute to improved public health outcomes by offering more accessible and timely diagnostic tools, potentially leading to earlier intervention and better prognoses for Arkansans. The development of novel biosensing technologies also aligns with Arkansas's growing biotechnology and advanced manufacturing sectors, creating opportunities for innovation and economic development.

This research area draws upon expertise in nanoparticles, drug delivery systems, and cancer cell biology. It involves collaborations that leverage advanced biosensing and bioanalysis techniques, contributing to a robust ecosystem of biomedical research within the state.